I got your point just fine, I know I seem stupid at times, but geez. I'm sure HSP's and Amphastar's products are also dissimilar, but not necessarily wrt something as obvious as a big disparity in average molecular weight. And you keep dodging my point, which is that I think FDA would have told Teva they were way off on the basic average molecular weight metric long ago, and that Teva would have done something different in response. So that if they actually started with Lupenox, that is very unlikely to be the current basis of their ANDA.
Regards, RockRat
Market Data 
Markets 
AI
